Keryx to Present at 14th Annual BIO CEO & Investor Conference; $KERX
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is an emerging, small-cap biopharma company developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent. Perifosine inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA).
Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
The company announced that Keryx CEO Ron Bentsur will be presenting at the 14th Annual Bio CEO & Investor Conference, to be held at the Waldorf-Astoria Hotel in New York City. Mr. Bentsur's presentation is scheduled to take place on Tuesday, February 14, 2012 at 9:00 a.m. ET.
A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.
Read more at MarketWatch.com.
ProActive Capital Indexes
See ProActive's Disclaimer